Summary: Erdosteine is a drug with a mucolytic effect, acting by increasing the production of mucus and reducing its viscosity, as well as improving mucociliary transport on the respiratory epithelium. It is widely used in the treatment of respiratory diseases, in particular acute bronchitis, chronic obstructive pulmonary disease (COPD) and chronic rhinitis and sinusitis. It is well tolerated and has a well-documented safety profile. In addition to its strictly mucolytic effect, it also has an antibacterial effect by reducing the ability of bacteria to attach to mucous membrane cells and intensifying the anti-adhesive effect of antibiotics. Erdosteine is not only the mucoregulator.
1. Mechanism of action of Erdosteine: breaks disulfide bonds present in the proteins that make up the mucu.
2. Pharmacological action: leads to thinning and changes the flow characteristics of mucus on the respiratory epithelium (reduces mucus viscosity, elasticity and ability to adhere), significantly improves mucociliary clearance, reduces mucus volume, thereby reducing symptoms such as coughing or shortness of breath.
3. Additional effects of Erdosteine: anti-inflammatory effect, antioxidant effect and antibacterial effect.
4. The latest research indicates its beneficial effects in infections caused by the SARS-CoV-2 virus and in the prevention of respiratory viral infections in children if used early enough Erdosteine is recommended for the treatment of respiratory diseases in children over 2 years of age and adults. Erdosteine is recommended by the National Antibiotic Protection Program for the treatment of productive cough in lower respiratory tract infections and by CHEST in the treatment of COPD patients, as the only mucoactive drug.